Earnings Call Summary | Sotera Health Company(SHC.US) Q1 2024 Earnings Conference
Earnings Call Summary | Sotera Health Company(SHC.US) Q1 2024 Earnings Conference
The following is a summary of the Sotera Health Company (SHC) Q1 2024 Earnings Call Transcript:
以下是Sotera Health Company（SHC）2024年第一季度财报电话会议记录的摘要：
Financial Performance:
财务业绩：
Sotera Health reported a revenue increase of 12.5% compared to Q1 2023, totaling $248 million.
Adjusted EBITDA saw a 13.7% growth compared to the first quarter of 2023 reaching $112 million.
Total company adjusted EBITDA margins climbed to 45.1%, and gross margin percentages were also up 50 basis points from Q1 2023.
Revenues of Sterigenics, Nordion, and Nelson Labs increased by 4.1%, 181%, and 10.8%, respectively.
Despite these improvements, the adjusted EPS remained at $0.13 per share, consistent with the same period last year.
Sotera Health报告称，与2023年第一季度相比，收入增长了12.5％，总额为2.48亿美元。
与2023年第一季度相比，调整后的息税折旧摊销前利润增长了13.7％，达到1.12亿美元。
公司调整后的息税折旧摊销前利润总利润率攀升至45.1％，毛利率百分比也比2023年第一季度增长了50个基点。
Sterigenics、Nordion和Nelson Labs的收入分别增长了4.1％、181％和10.8％。
尽管有这些改善，调整后的每股收益仍为0.13美元，与去年同期持平。
Business Progress:
业务进展：
All three business units of Sotera Health, namely Sterigenics, Nordion, and Nelson Labs, achieved growth in Q1 2024.
The company expressed confidence regarding pending lawsuits and preparedness for updated emission standards without significant additional capital expenditure.
They reaffirmed their 2024 outlook with expected revenue and adjusted EBITDA growth in the range of 4% to 6% compared to 2023.
Investment acceleration in Sterigenics' capacity expansions, Nordion's cobalt development programs, and US Ethylene Oxide (EO) facility enhancements is underway.
Improvements are forecasted for Nelson Labs' core testing, Sterigenics volumes, and across their operational excellence in managing supply in tight markets.
Capacity expansions are being implemented, with each set to start operations at different times over the next two years.
Sotera Health 的所有三个业务部门，即 Sterigenics、Nordion 和 Nelson Labs，均在 2024 年第一季度实现增长。
该公司对未决诉讼和为更新排放标准做好准备而无需大量额外资本支出表示了信心。
他们重申了2024年的展望，与2023年相比，预期收入和调整后的息税折旧摊销前利润增长在4％至6％之间。
对Sterigenics产能扩张、Nordion的钴开发计划和美国环氧乙烷 (EO) 设施改善的投资正在加速进行中。
预计Nelson Labs的核心测试、Sterigenics的产量及其在紧张市场中管理供应方面的卓越运营将有所改善。
正在实施产能扩张，每项扩建都将在未来两年的不同时间开始运营。
More details: Sotera Health Company IR
更多详情： Sotera 健康公司 IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多详情，请访问投资者关系网站。本文仅供投资者参考，不构成任何投资建议。
译文内容由第三方软件翻译。